Cipla Ltd · NSE:CIPLA
Cipla — Shareholder Meeting (July 2025)
18 slides from Cipla's shareholder meeting presentation, Jul 16, 2025
Slide 1: Proceedings of the 89th Annual General Meeting
16th July, 2025 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip
Slide 2: Address by Dr Y K Hamied, Chairman
Eighty-Nineth Annual General Meeting Address by Dr Y K Hamied on 16th July 2025, Chairman, Cipla Limited Dear Shareholders, Welcome to all of you at the 89th Annual General Meeting of your Company. This year, 2025, marks a significant milestone - Cipla will be 90 on 17th August. We are proud that ov
Slide 3: Chairman's address (continued)
us at Cipla, including you, our shareholders, I extend our gratitude and best wishes for his good health and well-being, as also for his continuing assistance to our Company. I would like to thank Samina Hamied for her positive role in Cipla over 20 years till 2024 as Executive Vice-Chairman of the
Slide 4: Annual General Meeting: MD & GCEO's Address
Annual General Meeting MD & GCEO’s Address Umang Vohra Jul 2025
Slide 5: FY25: Robust performance across geographies; highest ever EBITDA margin
FY25: Robust performance across geographies1; highest ever EBITDA margin Revenue EBITDA PAT FY25 INR 27,548 Cr 8% INR 7,128 Cr 14% INR 5,273 Cr 28% (YoY) (YoY) (YoY) 25.9% (139 bps YoY) 19.1% (301 bps YoY) Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR
Slide 6: Strategic focus driving steady expansion; Strong $1bn+ net cash position
Strategic focus driving steady expansion; Strong $1bn+ net cash position Revenue from Operations (in INR Cr) EBITDA & PAT Margin % 10% 26% ₹ 27,548 24% 5 Year CAGR ₹ 25,774 23% 22% 21% ₹ 22,753 ₹ 21,763 19% 19% ₹ 19,160 16% ₹ 17,132 13% 12% 12% 9% FY 20 FY 21 FY 22 FY 23 FY 24 FY 25 FY 20 FY 21 FY 2
Slide 7: Sustained Market Leadership: Key Highlights of the FY25
Sustained Market Leadership: Key Highlights of the FY25 South North Emerging India Africa America Markets 3rd 2nd 4th 2nd Largest pharma Largest pharma Largest by prescription Largest Indian company in India1 company in for generic inhalation exporter to emerging prescription market2 products in the
Slide 8: Maintaining Quality as a pillar of long-term success
Maintaining Quality as a pillar of long-term success Jun-24* Jul-24* Oct-24* Feb-25* Apr-25* Patalganga, Kurkumbh, Verna, Virgonagar, Medispray, Maharashtra Maharashtra Goa Bengaluru Goa 5 Manufacturing facilities were audited by the USFDA in FY25 All 5 inspections have been classified as ‘VAI’ *Mon
Slide 9: Commitment to Environmental Sustainability
Commitment to Environmental Sustainability Progress on ESG Goals Key Highlights ESG Ratings & Score Achieved 1.75 times water positive 79 B Achieved full compliance with the safe discharge targets Featured in the established by AMR Industry Alliance prestigious DJSI World (Climate & Water) Index & D
Slide 10: Cipla Foundation: Nurturing the Ecosystem of Care
Cipla Foundation: Nurturing the Ecosystem of Care In FY 2024-25, we touched the lives of 3,38,000+ individuals through our work across five thematic areas Environmental Health Education Skilling Disaster Response Sustainability • Palliative care • Water resource • Student learning • Upskilling • Rel
Slide 11: Accolades
Accolades Certificate of Appreciation: Gold Shield in Large Large Category (Listed Segment) Manufacturing & Trading sector at the ICSI National Awards for category at ICAI Awards for Excellence in Corporate Excellence in Financial Reporting Governance for FY 23-24 ‘Tuffies’ won the Health Awareness
Slide 12: Nurturing the business for the future (1/2)
Nurturing the business for the future (1/2) India South Africa • Nicotex1, Omnigel2 & Cipladine2 ranked #1 Wellness in respective categories • Ranked #3 in the SA OTC market3 • Secured revenues of ZAR 1.65 billion, • Acquisition of key brands i.e. Astaberry, growing at 11.8% over the last FY Ikin, B
Slide 13: Nurturing the business for the future (2/2)
Nurturing the business for the future (2/2) Respiratory Assets Pipeline Low Global Warming Potential Propellants Respiratory Assets Pipeline & • Filed 6 Respiratory assets including • Four key assets with Low Global Warming LGWP Propellants gSymbicort and gQvar in US Potential (LGWP) under developme
Slide 14: With 90 years of excellence, our purpose is our legacy
“With 90 years of excellence, our purpose is our legacy – it’s what sets us apart; driving us to continually innovate & provide care across continents, communities & generations”
Slide 15: Thank You
Cipla CARING FOR LIFE THANK YOU
Slide 16: Summary of proceedings of the 89th Annual General Meeting
Summary of proceedings of the 89th Annual General Meeting The 89th Annual General Meeting (AGM) of the members of Cipla Limited (the “Company”) was held on Wednesday, 16th July 2025, through Video Conferencing (VC). In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regula
Slide 17: Summary of proceedings (continued)
VC. Requisite quorum being present, the Company Secretary on behalf of the Chairman called the meeting to order and made the statutory announcements. The Company Secretary inter-alia informed the shareholders that: a) the meeting was being held through VC in accordance with the provisions of the Com
Slide 18: Summary of resolutions put up for shareholder approval
The summary of the resolutions put up for shareholder’s approval were as under: Sr. Agenda Item Type of No. Resolution Ordinary Business 1. To receive, consider and adopt the audited standalone financial statements of the Ordinary Company for the financial year ended 31st March, 2025 and the reports